US8137695B2
(en)
*
|
2006-08-18 |
2012-03-20 |
Arrowhead Madison Inc. |
Polyconjugates for in vivo delivery of polynucleotides
|
US20080281041A1
(en)
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
DE10214983A1
(de)
*
|
2002-04-04 |
2004-04-08 |
TransMIT Gesellschaft für Technologietransfer mbH |
Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
US8071560B2
(en)
*
|
2004-02-17 |
2011-12-06 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
AU2003268531A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US20060160759A1
(en)
*
|
2002-09-28 |
2006-07-20 |
Jianzhu Chen |
Influenza therapeutic
|
WO2006001810A2
(en)
*
|
2003-07-15 |
2006-01-05 |
California Institute Of Technology |
Improved inhibitor nucleic acids
|
US20050256071A1
(en)
*
|
2003-07-15 |
2005-11-17 |
California Institute Of Technology |
Inhibitor nucleic acids
|
WO2005017111A2
(en)
|
2003-07-15 |
2005-02-24 |
The Trustees Of The University Of Pennsylvania |
Methods and systems for identifying micro-rna targets and synthesizing novel micro-rnas and uses of the same
|
US20050060771A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Farmer Andrew Alan |
siRNA encoding constructs and methods for using the same
|
AU2005227870A1
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
CN1922197A
(zh)
*
|
2004-02-20 |
2007-02-28 |
吉尼西斯研究及发展有限公司 |
用于治疗IgE介导的失调的RNA干涉分子的靶向递送
|
WO2005110438A2
(en)
*
|
2004-04-15 |
2005-11-24 |
Massachusetts Institute Of Technology |
Methods and products related to the intracellular delivery of polysaccharides
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
WO2006085987A2
(en)
|
2004-07-09 |
2006-08-17 |
University Of Iowa Research Foundation |
Rna interference in respiratory epitheial cells
|
US20090313712A1
(en)
*
|
2004-08-25 |
2009-12-17 |
Leandro Christmann |
RNA interference and disease resistance in avians
|
US20080222743A1
(en)
*
|
2004-08-25 |
2008-09-11 |
Avigenics, Inc. |
RNA interference and disease resistance in avians
|
EP1797185B1
(en)
|
2004-09-24 |
2011-04-13 |
Alnylam Pharmaceuticals, Inc. |
Targeting opposite strand replication intermediates of single-stranded viruses by rnai
|
US20060089324A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Sailen Barik |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US7790878B2
(en)
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
EP1817416A2
(en)
*
|
2004-11-05 |
2007-08-15 |
Intradigm Corporation |
Compositions for treating respiratory viral infections and their use
|
US8138327B2
(en)
*
|
2004-11-23 |
2012-03-20 |
City Of Hope |
Inducible systems and methods for controlling siRNA expression
|
KR101169668B1
(ko)
*
|
2005-01-07 |
2012-08-07 |
알닐람 파마슈티칼스 인코포레이티드 |
RSV의 RNAi 조절 및 이를 위한 약제학적 조성물
|
WO2006113679A2
(en)
|
2005-04-15 |
2006-10-26 |
Board Of Regents, The University Of Texas System |
Delivery of sirna by neutral lipid compositions
|
NZ560936A
(en)
|
2005-02-03 |
2010-04-30 |
Benitec Inc |
RNAI expression constructs
|
WO2006086345A2
(en)
*
|
2005-02-07 |
2006-08-17 |
The Trustees Of Columbia University In The City Of New York |
Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
|
US8008468B2
(en)
*
|
2005-02-16 |
2011-08-30 |
Benitec, Inc. |
RNAi expression constructs with liver-specific enhancer/promoter
|
WO2006110688A2
(en)
*
|
2005-04-08 |
2006-10-19 |
Nastech Pharmaceutical Company Inc. |
Rnai therapeutic for respiratory virus infection
|
US20070213293A1
(en)
*
|
2005-04-08 |
2007-09-13 |
Nastech Pharmaceutical Company Inc. |
Rnai therapeutic for respiratory virus infection
|
JP2008537752A
(ja)
*
|
2005-04-12 |
2008-09-25 |
イントラディグム コーポレイション |
がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法
|
CA2606002A1
(en)
*
|
2005-04-28 |
2006-11-02 |
Benitec Limited |
Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns
|
US7199109B2
(en)
*
|
2005-06-03 |
2007-04-03 |
Cal Poly Pomona Foundation |
Potent inhibition of influenza virus by specifically designed short interfering RNA
|
US20100272769A1
(en)
*
|
2005-08-03 |
2010-10-28 |
Amcol International |
Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
|
US20080184618A1
(en)
*
|
2005-08-03 |
2008-08-07 |
Amcol International |
Virus-Interacting Layered Phyllosilicates and Methods of Use
|
US20070031512A1
(en)
*
|
2005-08-03 |
2007-02-08 |
Amcol International Corporation |
Virus-interacting layered phyllosilicates and methods of inactivating viruses
|
US20070099858A1
(en)
*
|
2005-10-03 |
2007-05-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated of inhibition of influenza virus gene expression using short interfering nucleic acid (siNA)
|
US20100129460A1
(en)
*
|
2005-10-14 |
2010-05-27 |
Nastech Pharmaceutical Company Inc. |
Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics
|
EP2202239A1
(en)
|
2005-11-01 |
2010-06-30 |
Alnylam Pharmaceuticals Inc. |
RNAI inhibition of influenza virus replication
|
JP2009514877A
(ja)
*
|
2005-11-04 |
2009-04-09 |
エムディーアールエヌエー,インコーポレイテッド |
siRNAの送達媒体としてのペプチド−ダイザ基質RNA抱合体
|
WO2007056861A1
(en)
*
|
2005-11-18 |
2007-05-24 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of influenza virus gene expression
|
CN100365122C
(zh)
*
|
2005-12-30 |
2008-01-30 |
中国疾病预防控制中心病毒病预防控制所 |
针对乙型流感病毒多聚酶基因的siRNA序列及其应用
|
CN100365123C
(zh)
*
|
2005-12-30 |
2008-01-30 |
中国疾病预防控制中心病毒病预防控制所 |
针对乙型流感病毒膜蛋白基因的siRNA序列及其应用
|
CN100365121C
(zh)
*
|
2005-12-30 |
2008-01-30 |
中国疾病预防控制中心病毒病预防控制所 |
针对乙型流感病毒核壳蛋白基因的siRNA序列及其应用
|
FI20060246A0
(fi)
|
2006-03-16 |
2006-03-16 |
Jukka Westermarck |
Uusi kasvua stimuloiva proteiini ja sen käyttö
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
US20100015232A1
(en)
*
|
2006-07-07 |
2010-01-21 |
Aarhus Universitet |
Nanoparticles for nucleic acid delivery
|
GB0613753D0
(en)
*
|
2006-07-11 |
2006-08-23 |
Norwegian Radium Hospital Res |
Method
|
WO2008014404A2
(en)
*
|
2006-07-26 |
2008-01-31 |
The University Of Chicago |
Receptor-mediated delivery : compositions and methods
|
US8017109B2
(en)
*
|
2006-08-18 |
2011-09-13 |
Roche Madison Inc. |
Endosomolytic poly(acrylate) polymers
|
CA2661093A1
(en)
*
|
2006-08-18 |
2008-02-21 |
Nastech Pharmaceutical Company Inc. |
Dicer substrate rna peptide conjugates and methods for rna therapeutics
|
FI20060751A0
(fi)
|
2006-08-23 |
2006-08-23 |
Valtion Teknillinen |
Menetelmä prostatasyövän hoitoon ja mainitusta menetelmästä hyödyntävien potilaiden seulonta
|
CA2661292A1
(en)
*
|
2006-08-24 |
2008-02-28 |
British Columbia Cancer Agency Branch |
Compositions and methods for treating myelosuppression
|
KR100817024B1
(ko)
*
|
2006-11-09 |
2008-03-26 |
재단법인 목암생명공학연구소 |
핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
|
US8168415B2
(en)
|
2007-02-07 |
2012-05-01 |
The Regents Of The University Of Colorado |
Axl fusion proteins as Axl tyrosine kinase inhibitors
|
EP2131848A4
(en)
*
|
2007-02-16 |
2012-06-27 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS FOR POTENTIATING THE ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES
|
WO2008112218A2
(en)
|
2007-03-12 |
2008-09-18 |
Antigen Express, Inc. |
Li-rnai involved li suppression in cancer immunotherapy
|
EP2146575A4
(en)
*
|
2007-04-12 |
2010-11-24 |
Alnylam Pharmaceuticals Inc |
INFLUENZA POLYNUCLEOTIDES, EXPRESSION CONSTRUCTS, COMPOSITIONS AND METHOD FOR THEIR USE
|
WO2008131419A2
(en)
*
|
2007-04-23 |
2008-10-30 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of rna interference agents
|
NZ581542A
(en)
*
|
2007-05-16 |
2012-02-24 |
Mat Malta Advanced Technologies Ltd |
Treatment and prevention of influenza
|
US8198256B2
(en)
|
2007-07-03 |
2012-06-12 |
Kyorin Pharmaceutical Co., Ltd. |
Treatment of influenza
|
US8716255B2
(en)
|
2007-08-10 |
2014-05-06 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
CN101367750B
(zh)
|
2007-08-14 |
2012-05-23 |
中国人民解放军军事医学科学院毒物药物研究所 |
(1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
|
AU2008334948B2
(en)
*
|
2007-12-13 |
2014-11-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for prevention or treatment of RSV infection
|
WO2010014755A1
(en)
*
|
2008-07-29 |
2010-02-04 |
The Regents Of The University Of Colorado |
Methods and compounds for enhancing anti-cancer therapy
|
EP2949752B1
(en)
|
2008-09-22 |
2017-12-20 |
RXi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
US20100168205A1
(en)
*
|
2008-10-23 |
2010-07-01 |
Alnylam Pharmaceuticals, Inc. |
Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
|
KR20220150995A
(ko)
*
|
2008-11-10 |
2022-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
US20100291188A1
(en)
*
|
2008-12-04 |
2010-11-18 |
Musc Foundation For Research Development |
Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
JP2012520085A
(ja)
*
|
2009-03-13 |
2012-09-06 |
エーゲン、インコーポレイテッド |
生物活性rnaの送達のための組成物及び方法
|
FI20090161A0
(fi)
|
2009-04-22 |
2009-04-22 |
Faron Pharmaceuticals Oy |
Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
|
SG10201402281WA
(en)
|
2009-05-12 |
2014-07-30 |
Romark Lab Lc |
Haloalkyl heteroaryl benzamide compounds
|
BRPI1014322A2
(pt)
*
|
2009-06-26 |
2015-08-25 |
Romark Lab Lc |
Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
|
DE102009031274A1
(de)
|
2009-06-30 |
2011-01-13 |
Justus-Liebig-Universität Giessen |
Liposomen zur pulmonalen Applikation
|
US8758996B2
(en)
*
|
2009-09-21 |
2014-06-24 |
Intelligent Medical Devices, Inc. |
Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of influenza A; influenza B; novel influenza A/H1N1; and a novel influenza A/H1N1 RNA sequence mutation associated with oseltamivir resistance
|
EP4089169A1
(en)
|
2009-10-12 |
2022-11-16 |
Larry J. Smith |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
EP3000885B1
(en)
|
2009-12-18 |
2018-07-25 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat hsf1-related diseases
|
WO2011098449A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
PL2539451T3
(pl)
*
|
2010-02-24 |
2016-08-31 |
Arrowhead Res Corporation |
Kompozycje do ukierunkowanego dostarczania siRNA
|
CN102985544A
(zh)
|
2010-04-23 |
2013-03-20 |
诺瓦提斯公司 |
治疗β-ENaC-相关疾病的有机组合物
|
LT2561078T
(lt)
*
|
2010-04-23 |
2019-01-10 |
Cold Spring Harbor Laboratory |
Naujos struktūriškai sukonstruotos shrnr
|
WO2012119095A1
(en)
|
2011-03-02 |
2012-09-07 |
Board Of Regents, The University Of Texas System |
Fus1/tusc2 therapies
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
FI20115640A0
(fi)
|
2011-06-22 |
2011-06-22 |
Turun Yliopisto |
Yhdistelmähoito
|
WO2013030778A2
(en)
|
2011-09-02 |
2013-03-07 |
Novartis Ag |
Organic compositions to treat hsf1-related diseases
|
FI20115876A0
(fi)
|
2011-09-06 |
2011-09-06 |
Turun Yliopisto |
Yhdistelmähoito
|
US20130122096A1
(en)
*
|
2011-11-14 |
2013-05-16 |
Silenseed Ltd. |
Compositions for drug delivery and methods of manufacturing and using same
|
JP2015507474A
(ja)
*
|
2011-12-23 |
2015-03-12 |
エーゲン、インコーポレイテッド |
生物活性rnaの送達のための組成物及び方法
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
MX2014013367A
(es)
|
2012-05-02 |
2014-12-08 |
Novartis Ag |
Composiciones organicas para tratar enfermedades relacionadas con kras.
|
US9868952B2
(en)
|
2012-07-08 |
2018-01-16 |
Sirnaomics, Inc. |
Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
|
ES2627500T3
(es)
|
2012-07-13 |
2017-07-28 |
Turun Yliopisto |
Terapia de combinación
|
CN110464709A
(zh)
|
2012-08-10 |
2019-11-19 |
德克萨斯州大学系统董事会 |
用于治疗中风的神经保护性脂质体组合物和方法
|
US9801953B2
(en)
|
2012-10-15 |
2017-10-31 |
Emory University |
Nanoparticles carrying nucleic acid cassettes for expressing RNA
|
CA2902393C
(en)
|
2013-02-28 |
2022-11-01 |
Arrowhead Research Corporation |
Organic compositions to treat epas1-related diseases
|
US9693958B2
(en)
|
2013-03-15 |
2017-07-04 |
Cureport, Inc. |
Methods and devices for preparation of lipid nanoparticles
|
WO2015051135A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compositions to treat hepcidin-related diseases
|
WO2016011123A1
(en)
|
2014-07-16 |
2016-01-21 |
Arrowhead Research Corporation |
Organic compositions to treat apoc3-related diseases
|
WO2016038550A1
(en)
|
2014-09-11 |
2016-03-17 |
Novartis Ag |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
WO2016065282A1
(en)
*
|
2014-10-24 |
2016-04-28 |
The Regents Of The University Of Michigan |
Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
|
US10479997B2
(en)
|
2014-12-01 |
2019-11-19 |
Novartis Ag |
Compositions and methods for diagnosis and treatment of prostate cancer
|
US20180296537A1
(en)
|
2015-06-05 |
2018-10-18 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
US9856481B2
(en)
|
2015-08-13 |
2018-01-02 |
Ann & Robert H. Lurie Children's Hospital |
MicroRNA treatment of fibrosis
|
WO2017106814A1
(en)
|
2015-12-18 |
2017-06-22 |
The Board Of Regents Of The University Of Texas System |
Therapeutics for preterm labor management
|
KR101712856B1
(ko)
*
|
2016-06-16 |
2017-03-07 |
재단법인 한국파스퇴르연구소 |
인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
|
WO2018047148A1
(en)
|
2016-09-12 |
2018-03-15 |
Novartis Ag |
Compounds for the inhibition of mirna
|
JP7041136B2
(ja)
|
2016-10-12 |
2022-03-23 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Tusc2免疫療法のための方法および組成物
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
US10597657B2
(en)
|
2017-09-11 |
2020-03-24 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
EP3788138A1
(en)
|
2018-05-02 |
2021-03-10 |
Novartis AG |
Regulators of human pluripotent stem cells and uses thereof
|
EP3870700A1
(en)
|
2018-10-24 |
2021-09-01 |
Codiak BioSciences, Inc. |
Methods to improve potency of electroporation
|
EP3920889A4
(en)
|
2019-02-08 |
2022-12-07 |
Board of Regents, The University of Texas System |
TELOMERASE-CONTAINING EXOSOMES FOR THE TREATMENT OF DISEASES RELATED TO AGE-RELATED ORGANDYS FUNCTION
|
WO2021160937A1
(en)
|
2020-02-11 |
2021-08-19 |
Turun Yliopisto |
Therapy of ras-dependent cancers
|
WO2021211923A1
(en)
*
|
2020-04-16 |
2021-10-21 |
Pulmoquine Therapeutics, Inc. |
Compositions and methods for treating disease
|
CN115996707A
(zh)
|
2020-04-20 |
2023-04-21 |
德克萨斯大学系统董事会 |
生物活性干粉组合物及其制造和使用方法
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
US20230302154A1
(en)
|
2020-08-19 |
2023-09-28 |
The Board Of Regents Of The University Of Texas System |
Nanodrugs for targeted drug delivery and use thereof
|
EP4204447A1
(en)
|
2020-08-28 |
2023-07-05 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
WO2023225160A1
(en)
|
2022-05-18 |
2023-11-23 |
The Children's Hospital Of Philadelphia |
Compositions and methods for inducible alternative splicing regulation of gene expression
|